EOS-984 is under clinical development by ITeos Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EOS-984’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EOS-984 is under development for the treatment of advanced solid tumors. The drug candidate is administered through oral route. It acts by targeting equilibrative nucleoside transporter 1 (ENT1) and is additive to A2AR antagonist.
ITeos Therapeutics overview
iTeos Therapeutics is a clinical-stage biopharmaceutical company. It discovers and develops immuno-oncology drugs for cancer. The company’s pipeline products are EOS-448, EOS-984, dostarlimab, iberdomide, pembrolizumab, CD96 drug candidates. Its products are used to treat various cancers like advanced malignancies, relapsed refractory multiple myeloma. The drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations. Its service includes to carries out clinical trials for inupadenant, an A2A receptor antagonist, as a treatment for solid tumors in monotherapy. It has operational presence in the US; and Belgium. iTeos Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of EOS-984’s drug-specific PTSR and LoA scores, buy the report here.